Hoylecohen LLC Has $954,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Hoylecohen LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,220 shares of the company’s stock after purchasing an additional 920 shares during the period. Hoylecohen LLC’s holdings in Novo Nordisk A/S were worth $954,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. U.S. Capital Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after acquiring an additional 90 shares during the last quarter. Clarius Group LLC raised its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after buying an additional 95 shares during the last quarter. Montag A & Associates Inc. boosted its holdings in shares of Novo Nordisk A/S by 1.0% during the 4th quarter. Montag A & Associates Inc. now owns 9,492 shares of the company’s stock worth $982,000 after buying an additional 96 shares during the period. Finally, 9258 Wealth Management LLC grew its stake in Novo Nordisk A/S by 4.0% in the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock valued at $260,000 after buying an additional 97 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NVO traded up $0.47 on Friday, hitting $136.04. 2,845,222 shares of the stock traded hands, compared to its average volume of 4,075,833. The business has a fifty day moving average price of $128.21 and a two-hundred day moving average price of $116.45. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $610.48 billion, a PE ratio of 46.91, a P/E/G ratio of 1.40 and a beta of 0.43. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. On average, research analysts predict that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.